Telik's product development focus is on cancer and other serious diseases. We currently have two product candidates in clinical development:

GST P1-1 ROLE IN CANCER A variety of human cancers, including breat, colon, kidney, lung and ovarian, usually express high levels of GST P1-1 compared to the surrounding tissues. High expression of GST P1-1 has been associated with disease progression and with drug resistance in patients undergoing chemotherapy. Learn more about GST P1-1

TELINTRA® (Ezatiostat HCl) A small molecule bone marrow stimulant that is in a Phase 2 trial in myelodysplastic syndrome (MDS) and severe chronic idiopathic neutropenia (SCN). Learn more about TELINTRA®

TELCYTA® (Canfosfamide HCl) A cancer cell-activated small molecule that is in development for ovarian and non-small cell lung cancer. Learn more about TELCYTA®

Preclinical Pipeline Additional potential product candidates in our pipeline have resulted from our ongoing discovery research programs and our collaborations with leading cancer centers. These include a tetravalent alkylator, inhibitors of enzymes we believe are critical to the growth of cancer cells, and other compounds directed toward critical cancer cell growth mechanisms. View preclinical pipeline

Sitemap Contact Legal Notice Telik Home